Fifty-three percent of Latinx and 49% of Black Medicare beneficiaries choose enrollment in Medicare Advantage; seeing average annual savings of $1,113 and $1,270, respectively, compared to Traditional Medicare.
New data released by Better Medicare Alliance, a research and advocacy group supporting Medicare Advantage, shows Medicare Advantage’s continued strength with diverse beneficiary populations.
The study, by ATI Advisory and based on 2018 Medicare Current Beneficiary Survey (MCBS) data finds 53% of Latinx Medicare beneficiaries choose enrollment in Medicare Advantage, as do 49% of Black beneficiaries.
Survey data shows Latinx beneficiaries spend $1,113 less when enrolled in Medicare Advantage compared with Traditional Fee-for-Service (FFS) Medicare, while Black beneficiaries see average savings of $1,270.
In addition, findings depict how Medicare Advantage beneficiaries of all races and ethnicities are more medically complex than those in Traditional FFS Medicare. Between 50-52% of Black, white, and Latinx Medicare Advantage beneficiaries report more than three chronic conditions, compared with 45-48% of Traditional FFS Medicare beneficiaries.
MCBS data also shows that Medicare Advantage beneficiaries are more likely to receive routine care than those enrolled in Traditional FFS Medicare. This includes higher rates of beneficiaries receiving mammograms, flu shots, blood pressure screenings, and cholesterol checks.
“Once again, the research demonstrates that Medicare Advantage is the preferred coverage choice for minority, lower-income, and medically complex beneficiaries – and is delivering meaningful cost savings and more preventive care as compared to Traditional Medicare,” Allyson Y. Schwartz, president and CEO of the Better Medicare Alliance, said. “With over 26.5 million beneficiaries enrolled in Medicare Advantage today, this report shows that minority beneficiaries are a driving force behind these enrollment gains; turning to Medicare Advantage to meet their health and social needs. When policymakers stand up for Medicare Advantage, they stand up for these seniors, too.”
Additional key findings from the study are below:
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More